Abstract
Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder often linked to gut dysbiosis. While Fecal Microbiota Transplantation (FMT) has shown promise in short-term studies, long-term data is scarce. This retrospective study followed 227 patients with moderate-to-severe IBS for up to 60 months post-FMT. Results indicate that FMT is safe and effective, with peak efficacy at 3 months (~74.6%). However, the benefits tend to wane over time, suggesting that periodic "booster" treatments are necessary to maintain clinical remission and improve patient quality of life.
Introduction
Irritable Bowel Syndrome (IBS) affects a significant portion of the global population, characterized by abdominal pain, bloating, and altered bowel habits. The pathophysiology is complex, but the role of the gut microbiome is increasingly recognized as a central factor. Conventional therapies, including dietary changes and probiotics, often fail to provide long-term relief for moderate-to-severe cases. Fecal Microbiota Transplantation (FMT) aims to restore microbial diversity by transferring stool from healthy donors. This study, published in Frontiers in Medicine, evaluates the five-year durability and safety of FMT in a large clinical cohort, addressing a critical gap in the literature regarding long-term outcomes.
Methods
This single-center, retrospective study conducted at Shanghai Tenth People’s Hospital included 227 patients with an IBS Severity Scoring System (IBS-SSS) score greater than 175. The cohort represented various subtypes: 47.58% IBS-C (constipation), 39.21% IBS-D (diarrhea), and 13.22% IBS-M (mixed).
Patients received FMT via one of three routes: nasointestinal tube (NIT), colonoscopy, or oral capsules. To ensure consistency, a "universal donor" (a healthy 24-year-old student) was utilized. Follow-up assessments were conducted at 1, 3, 6, 12, 24, 36, 48, and 60 months. At the 12-month mark, patients whose IBS-SSS scores remained high (> 175) were eligible for repeat FMT treatments.
Results
The treatment demonstrated significant efficacy, peaking at 3 months with a 74.62% response rate. Efficacy remained relatively stable between 60% and 75% throughout the 5-year period, supported by the protocol's allowance for repeat treatments. Specifically, efficacy rates were 71.54% at 12 months and 62.71% at 60 months.
Significant improvements were observed across multiple clinical metrics. The mean IBS-SSS score dropped from a baseline of 321.37 (severe) to significantly lower levels throughout the follow-up. Abdominal pain severity and distension/bloating scores showed marked reductions, reaching their lowest points around the 12-month mark before stabilizing.
Beyond gastrointestinal symptoms, FMT significantly improved systemic well-being. The IBS-specific quality of life (IBS-QoL) score improved from 40.24 at baseline to 50.13 at 3 months. Similarly, fatigue levels, measured by the Fatigue Assessment Scale (FAS), dropped from 47 at baseline to 32.58 at 3 months. Safety was well-established; while 39.21% of patients experienced mild, transient side effects like temporary bloating, no serious adverse events were recorded over the five-year period.
Discussion
The findings suggest that FMT is a viable long-term management strategy for IBS. However, the observed "waning" effect—where efficacy peaks early and then gradually declines—indicates that donor microbiota may not permanently colonize the host environment. This suggests that FMT should be viewed as a manageable, periodic therapy rather than a one-time cure.
Interestingly, the oral capsule group showed the highest efficacy rate at 36 months (88.46%), likely due to better patient compliance and the ease of administering repeated doses compared to more invasive routes. The improvement in fatigue and QoL scores further reinforces the "gut-brain axis" theory, suggesting that restoring gut health has systemic benefits for psychological and physical health.
Conclusion
Based on 60 months of follow-up, FMT is a safe and effective intervention for moderate-to-severe IBS. To sustain clinical benefits over the long term, clinicians should consider periodic, repetitive FMT treatments tailored to the individual patient's symptom trajectory.
Summary updated